5613260 A PHASE -- IIA-IIB, OPEN LABEL, SINGLE CENTER TRIAL TO STUDY SAFETY, TOLERABILITY AND EFFICACY OF MEMANTINE AS SUPPORTIVE LONG-TERM TREATMENT OF SICKLE CELL PATIENTS: TRIAL DESIGN AND ENROLLMENT

Lignende værker

• 5613260 A PHASE -- IIA-IIB, OPEN LABEL, SINGLE CENTER TRIAL TO STUDY SAFETY, TOLERABILITY AND EFFICACY OF MEMANTINE AS SUPPORTIVE LONG-TERM TREATMENT OF SICKLE CELL PATIENTS: TRIAL DESIGN AND ENROLLMENT
  af: C.L. Levin, et al.
  Udgivet: (2023-04-01)
• Iron metabolism and genetic modifiers in thalassemia and sickle cell anemia
  af: Gunay Aliyeva, et al.
  Udgivet: (2026-04-01)
• PB2222: THE PROTECTIVE EFFECT OF THE SPLEEN IN SICKLE CELL PATIENTS. A COMPARATIVE STUDY BETWEEN PATIENTS WITH ASPLENIA AND HYPERSPLENISM.
  af: S. Peretz, et al.
  Udgivet: (2022-06-01)
• MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease
  af: Inga Hegemann, et al.
  Udgivet: (2020-08-01)
• BACK TO THE “GOLD STANDARD”: HOW PRECISE IS HEMATOCRIT DETECTION TODAY?
  af: Leonid Livshits, et al.
  Udgivet: (2022-06-01)